0000000000527925
AUTHOR
Linda Cardozo
How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study
Objective To determine the prevalence of chronic and debilitating symptoms of the overactive bladder, defined here as the presence of chronic frequency, urgency and urge incontinence (either alone or in any combination), and presumed to be caused by involuntary detrusor contractions. Subjects and methods Data were collected using a population-based survey (conducted by telephone or direct interview) of men and women aged 40 years, selected from the general population in France, Germany, Italy, Spain, Sweden and the United Kingdom, using a random stratified approach. The main outcome measures were: prevalence of urinary frequency (> 8 micturitions/24 h), urgency and urge incontinence; the p…
Can we prevent incontinence?: ICI-RS 2011
Aims A review of the current state of research with regard to prevention of incontinence. Methods The search was limited to English language publications on the topic of incontinence prevention. Results Incontinence is associated with a range of risk factors, most of which are modifiable. Lifestyle changes with behavioral modifications that can prevent urinary incontinence (UI) need to be adopted from an early phase of life. Pregnancy per se for the woman, independent of labor and delivery practice, is a risk factor for UI. The influence of estrogen is still under discussion as to its direct influence to UI. For both men and women, there is a correlation between pelvic-floor related surgery…
Mirabegron in overactive bladder: A review of efficacy, safety, and tolerability
Aims Mirabegron, the first β3-adrenoceptor agonist to enter clinical practice, has a different mechanism of action from antimuscarinic agents. This review presents data on the efficacy, safety, and tolerability of mirabegron in studies conducted to date. Methods All clinical data on mirabegron that are currently in the public domain are included, including some in-press manuscripts. Results In Phase III clinical trials in patients with overactive bladder (OAB), mirabegron at daily doses of 25, 50, and 100 mg demonstrated significant efficacy in treating the symptoms of OAB, including micturition frequency, urgency incontinence, and urgency. Significant improvements in micturition frequency,…